Before a two-year-old ever receives the one-time infusion the headlines are calling a cure, there is a stretch of days no press release pictures. The child’s own blood stem cells are drawn and shipped to a lab to be edited. Then, to clear room for the edited cells to take hold, the child is given a full course of busulfan, the myeloablative chemotherapy that empties the bone marrow. It is the conditioning used before a transplant, and it does what that chemo does. It carries a risk of infertility. In the studies that supported this approval, it killed a child.
The FDA’s July 1 announcement does not linger on any of that. The supplemental approval extends Casgevy, Vertex Pharmaceuticals’ CRISPR gene therapy, to children as young as two with sickle cell disease and recurrent vaso-occlusive crises, or with transfusion-dependent beta thalassemia. It had been cleared down to age twelve. Now it reaches toddlers, in 53 days, at a list price of $2.2 million, for an age group that never appeared in the trials. The announcement leads with the milestone. The rest is in the fine print.
Start with what the agency actually had, because it is thinner than the word “cleared” suggests. The pediatric data came from children ages five to eleven, presented at the hematology meeting last December. In the sickle cell study, eleven children were dosed, and all eight who had reached a full year of follow-up had gone at least twelve straight months without a severe crisis, averaging about nineteen. In the thalassemia study, fifteen children enrolled, and the eight who had reached a year were all off transfusions, a mean of roughly twenty-three months. Strong numbers on a small base. For a family watching a child cycle through crisis after crisis, they are the kind of numbers that rearrange a life.
But the approval reaches down to age 2, and no child that young was in those studies. The youngest children Vertex dosed were 5. The agency extended the therapy to two-, three-, and four-year-olds on extrapolation, on the reasonable-sounding premise that a toddler’s marrow will behave like a six-year-old’s. Reasonable is not demonstrated. The FDA approved a gene therapy for an age group its pivotal data never enrolled, and the announcement does not foreground that gap.
Then the conditioning, which every patient has to survive before the edited cells go in. Reporting on the rollout has been blunt about the cost: the busulfan carries a risk of infertility serious enough that Vertex’s own label tells physicians to raise fertility preservation with families before treatment. For a two-year-old that is not a conversation with the patient. It is a decision made over a child who cannot weigh it. During the younger-children program, one patient, a child with thalassemia, developed severe veno-occlusive disease from the busulfan conditioning and died of pneumonia amid multi-organ failure. Vertex notes, correctly, that the death traced to the conditioning and not to the CRISPR edit. The distinction is clinically true. It does not survive the plain fact that you cannot get the edit without the conditioning.
The price is $2.2 million. That is the list, before the hospital stay and the months of monitoring the process demands, for a therapy aimed at a disease that in this country falls hardest on Black families and leans heavily on Medicaid. A one-time treatment priced past two million dollars is an engineering achievement and a stress test for every state program that will be asked to pay for it.
Which brings up how fast this moved. The FDA cleared the pediatric expansion in 53 days, the eighth approval selected under the Commissioner’s National Priority Voucher, the pilot Commissioner Marty Makary launched in 2025 to compress reviews from the usual ten to twelve months down to one or two. On its face that is speed in the service of sick children, and it is easy to cheer. Read the program’s design and a second picture surfaces. The voucher is discretionary, and the agency has been open that it favors companies committing to White House priorities, among them the administration’s drug-pricing deals and reshoring manufacturing into the United States. STAT’s reporting on the first rounds found the pathway threaded through the White House, the awards clustering among large drugmakers already doing business with the administration. A voucher decides whose application jumps the line. Its criteria bleed from public-health urgency into industrial policy and pricing arrangements the public never gets to read.
None of that is canceled out by the benefit, and the benefit is not in dispute. Both things hold at once, and the speed does not sanctify what it cleared. A two-month review of a therapy that requires myeloablative chemo, carries a conditioning-related death in its record, and reaches an age group its trials never enrolled is not the same event as a two-month review that has earned the public’s trust. Fast is a description. It is not a finding.
None of this argues the drug should not exist. The disease it treats spends childhoods putting kids in the hospital in pain, and a therapy that ends that is worth having. But “first gene therapy for young children” is a marketing line, and the approval underneath it was assembled out of small trials, brutal conditioning, a seven-figure price, and a review clock set by a program that has learned to reward the companies willing to deal. Toddlers can get the therapy now. The youngest child anyone studied was five.
Sources
- FDA – FDA Approves First Gene Therapy for Young Children With Sickle Cell Disease (2026-07-01)
- Vertex Pharmaceuticals – new CASGEVY data in children ages 5–11, ASH annual meeting
- Managed Healthcare Executive – positive Casgevy results with one patient death from busulfan conditioning, ASH 2025
- Scripps News – breakthrough sickle-cell treatment and infertility risk from conditioning
- BioPharma Dive – pricing of the CRISPR sickle-cell therapies
- FDA – Commissioner’s National Priority Voucher (CNPV) Pilot Program
- STAT – how pharmaceutical companies won FDA priority review vouchers
- Fierce Biotech – FDA names Regeneron and Sanofi among first recipients of 1- to 2-month priority review vouchers